La chaîne d'options affiche les données clés des options sur actions de Kyverna Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Kyverna Therapeutics..

Kyverna Therapeutics (NASDAQ:KYTX) Stock, Chaîne d'Options

Kyverna Therapeutics

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics Inc

Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) will release earnings results for the second quarter, after the <a href="https://www.benzinga.com/quote/aa/earnings">closing bell on Wednesday, July 16.</a>
Analysts expect the Pittsburgh, Pennsylvania-based company to report quarterly earnings at 51 cents per share, up from 16 cents per share in the year-ago period. Alcoa projects to report quarterly revenue at $2.96 billion, compared to $2.91 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 14, Alcoa and its joint venture partner announced that San Ciprián smelter operations will be delayed to mid-2026 following a national power outage.
Alcoa shares fell 4.2% to close at $29.79 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/AA/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Citigroup analyst Alexander Hacking reinstated a Buy rating with a price target of $42 on July 8, 2025. This analyst has an accuracy rate of 66%.</li>
<li>B. Riley Securities analyst Lucas Pipes maintained a Buy rating and cut the price target from $43 to $38 on June 24, 2025. This analyst has an accuracy rate of 68%.</li>
<li>UBS analyst Daniel Major downgraded the stock from Buy to Neutral with a price target of $31 on May 15, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Morgan Stanley analyst Carlos De Alba maintained an Overweight rating and cut the price target from $51 to $39 on April 9, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Jefferies analyst Chris LaFemina maintained a Buy rating and cut the price target from $50 to $45 on Jan. 6, 2025. This analyst has an accuracy rate of 62%.</li>
</ul>
Considering buying AA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/AA/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="570" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15052529/image-164-1024x570.png" alt="" class="wp-image-985500" style="width:614px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15052529/image-164-1024x570.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15052529/image-164-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15052529/image-164-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15052529/image-164.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46408189/jpmorgan-wells-fargo-and-3-stocks-to-watch-heading-into-tuesday">JPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

Alcoa Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

WIIM

LQR House shares are trading lower after the company announced a $46 million offering.

Piper Sandler analyst Nathan Race assumes West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTBA#NASDAQ">WTBA</a>) with a Neutral rating and announces Price Target of $21.5.

Initiation

WTBA

Piper Sandler Assumes West Bancorp at Neutral, Announces Price Target of $21.5

UBS analyst Douglas Harter maintains PennyMac Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) with a Neutral and raises the price target from $110 to $115.

PFSI

UBS Maintains Neutral on PennyMac Financial Servs, Raises Price Target to $115

Financial and Strategic Considerations
Carbon-offset-enabled trades may command price premiums over traditional contracts. Based on initial modeling and comparable market data, Davis Commodities anticipates potential incremental high-margin revenue of $10–$15 million by the end of 2026, subject to execution timelines, client uptake, and market conditions.
This initiative complements Davis Commodities' broader commitment to sustainable trade infrastructure and builds on recent developments in blockchain traceability, tokenized trade models, and the company's exploration of a Solana-based digital reserve strategy.

DTCK

Davis Commodities Anticipates Potential Incremental High-Margin Revenue Of $10M - $15M By The End Of 2026

General

IXHL

CORRECTION: Incannex Healthcare Appointed Douglas Kirsch To Its Advisory Board On June 24

UBS analyst Douglas Harter maintains Finance of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOA#NYSE">FOA</a>) with a Neutral and raises the price target from $22.5 to $25.

UBS Maintains Neutral on Finance of America, Raises Price Target to $25

Piper Sandler analyst Derek Podhaizer initiates coverage on ProFrac Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACDC#NASDAQ">ACDC</a>) with a Neutral rating and announces Price Target of $8.

ACDC

Piper Sandler Initiates Coverage On ProFrac Holding with Neutral Rating, Announces Price Target of $8

UBS analyst Douglas Harter maintains Blackstone Mortgage Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXMT#NYSE">BXMT</a>) with a Neutral and raises the price target from $19.5 to $20.

BXMT

UBS Maintains Neutral on Blackstone Mortgage Trust, Raises Price Target to $20

<a href="https://www.wto.org/english/news_e/news25_e/stat_15jul25_e.htm" title="https://www.wto.org/english/news_e/news25_e/stat_15jul25_e.htm">https://www.wto.org/english/news_e/news25_e/stat_15jul25_e.htm</a>

Macro Economic Events

Macro Notification

Global

Econ #s

Economics

World Trade Organization Report Says Volume Of World Merchandise Trade Rose 3.6% In Q1 Of 2025 From Previous Quarter; Imports Surged In North America In Anticipation Of Higher Tariffs In The United States

Three-year-old Habebat Allah lost both arms and a leg in a missile strike during the ongoing war in Gaza, while eight-year-old Sidra Al Bordeeni hadn't been on a bike since the missile strike that tore through her school in <a href="https://www.benzinga.com/news/politics/25/07/46212181/trump-says-israel-ready-for-60-day-ceasefire-in-gaza-hopes-hamas-takes-the-deal-because-it-wont-get-better">Gaza</a> a year ago. She lost her right arm during the explosion at Nuseirat School, where she and her family had sought shelter from airstrikes,<a href="https://www.reuters.com/world/asia-pacific/karachi-gaza-pakistani-startup-ships-prosthetics-child-war-survivors-2025-07-07/"> Reuters</a> reports.
Sidra's mother, Sabreen, said hospitals were overwhelmed, and with no way to leave, there was no chance of saving her daughter's hand. According to Reuters, Sidra's return to two wheels came after a life-changing fitting in a Jordanian clinic, where she received a custom-made prosthetic arm built in Karachi, Pakistan, over 4,000 kilometers away.
"She's out playing, and all her friends and siblings are fascinated by her arm," her mother told Reuters.
Don't Miss:
<ul class="wp-block-list">
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
<li>This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?">You Can Become an Investor for Just $500.25</a></li>
</ul>
<h2 class="wp-block-heading">The Startup Using Phones, 3D Printers, and Hope to Reach Conflict Zones</h2>
Bioniks, the Pakistani <a href="https://www.benzinga.com/news/topics/25/07/46334253/stanford-phd-building-superhumanoids-says-robots-wont-replace-us-theyll-supercharge-people-as-1-65b-startup-eyes-ipo">startup</a> behind the arm, was founded in 2021 by entrepreneur Anas Niaz. According to Reuters, the company uses a mobile app to gather visual data from patients and create 3D models for affordable, custom prosthetics.
To help children embrace their new limbs, Bioniks sometimes designs prosthetics inspired by characters like Marvel's Iron Man or Disney's Elsa, adding a sense of play and identity to daily use, Reuters says. The entire process, from assessment to production, can happen remotely, allowing children in closed-off areas to access care without crossing borders.&nbsp;
Since launching, Bioniks has built over 1,000 prosthetic limbs inside Pakistan, but Sidra and Habebat were their first international patients, Reuters reports. Niaz flew from Karachi to Amman to personally deliver both prosthetics after completing a series of virtual fittings.
Sidra's arm was funded by Mafaz Clinic in Jordan, while donations from Pakistan paid for Habebat's devices. Mafaz CEO Entesar Asaker told Reuters that their clinic chose Bioniks for its low price, remote solutions, and ability to troubleshoot virtually.
Trending: $100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.
<h2 class="wp-block-heading">Gaza&#8217;s Health System Collapsed But This Solution Filled the Void</h2>
Most high-end prosthetics range between $10,000 and $20,000, but Bioniks' versions cost roughly $2,500 per unit, Reuters says. While less complex than American models, they are lighter and easier for children to use, especially in rough terrain and temporary housing. The design also allows for long-term reuse, as many components stay intact and can be recycled to help other children as they grow.
The United Nations estimated in a March<a href="https://www.unocha.org/publications/report/occupied-palestinian-territory/humanitarian-situation-update-275-gaza-strip"> report</a> that Gaza had at the time more than 4,500 new amputees since the war began in October 2023. That adds to 2,000 existing cases, with children representing a significant portion of those injured.
Gaza's hospitals have been described by the<a href="https://www.who.int/publications/m/item/virtual-press-conference-on-global-health-issues-transcript-10-january-2024"> World Health Organization</a> spokesperson Christian Lindmeier as being "on their knees," which makes external solutions essential for survival.
See Also: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
<h2 class="wp-block-heading">A Bracelet, a Heart Shape, and a Message To Her Father</h2>
Sidra now wears a small bracelet on her prosthetic hand. According to Reuters, she used both hands to form a heart for the first time since the attack and sent a photo of the gesture to her father, who remains in Gaza.
"What I'm looking forward to most is using both my arms to finally hug my father when I see him," she said.
Bioniks plans to expand next to war zones like Ukraine, though Niaz says funding remains their biggest challenge. Reuters says the company is looking for sponsors and partners to scale faster and reach more children globally.
Until then, girls like Sidra are carrying a message on two arms: progress can start with one good hand and a little imagination.
Read Next: <a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a>
Image: Shutterstock

3-Year-Old Lost Both Arms And A Leg In Gaza — Now She's Wearing A Marvel-Inspired Prosthetic From Startup Bioniks

Davis Commodities Plans To Establish Carbon Credit Trading Unit As Part Of ESG And Digital Integration Strategy

Piper Sandler analyst Derek Podhaizer initiates coverage on Ranger Energy Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNGR#NYSE">RNGR</a>) with a Neutral rating and announces Price Target of $13.

RNGR

Piper Sandler Initiates Coverage On Ranger Energy Services with Neutral Rating, Announces Price Target of $13

UBS analyst Douglas Harter maintains Apollo Comml Real Est (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARI#NYSE">ARI</a>) with a Neutral and raises the price target from $10 to $10.5.

UBS Maintains Neutral on Apollo Comml Real Est, Raises Price Target to $10.5

MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) has outperformed the market over the past 5 years by 1.33% on an annualized basis producing an average annual return of 15.38%. Currently, MetLife has a market capitalization of $52.39 billion. 
Buying $1000 In MET: If an investor had bought $1000 of MET stock 5 years ago, it would be worth $2,007.80 today based on a price of $77.92 for MET at the time of writing.
<h3>MetLife's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752588917_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In MetLife 5 Years Ago Would Be Worth Today

Piper Sandler analyst Derek Podhaizer initiates coverage on RPC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RES#NYSE">RES</a>) with a Underweight rating and announces Price Target of $5.

Piper Sandler Initiates Coverage On RPC with Underweight Rating, Announces Price Target of $5

<a href="https://truthsocial.com/@realDonaldTrump/posts/114857569436636352" title="https://truthsocial.com/@realDonaldTrump/posts/114857569436636352">https://truthsocial.com/@realDonaldTrump/posts/114857569436636352</a>

Politics

iShares MSCI Indonesia Investable Market Index Fund

EIDO

Earlier: President Trump Posts On Truth Social "Great deal, for everybody, just made with Indonesia. I dealt directly with with their highly respected President. DETAILS TO FOLLOW!!!"

<a href="https://truthsocial.com/@realDonaldTrump/114857639804190832">https://truthsocial.com/@realDonaldTrump/114857639804190832</a>

President Trump Posts On Truth Social "Fed should cut Rates by 3 Points. Very Low Inflation. One Trillion Dollars a year would be saved!!!"

Piper Sandler analyst Derek Podhaizer initiates coverage on ProPetro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PUMP#NYSE">PUMP</a>) with a Neutral rating and announces Price Target of $7.

PUMP

Piper Sandler Initiates Coverage On ProPetro Holding with Neutral Rating, Announces Price Target of $7

Piper Sandler analyst Derek Podhaizer initiates coverage on Patterson-UTI Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTEN#NASDAQ">PTEN</a>) with a Neutral rating and announces Price Target of $7.

PTEN

Piper Sandler Initiates Coverage On Patterson-UTI Energy with Neutral Rating, Announces Price Target of $7

Legal

Press Releases

Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT)

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Kyverna Therapeutics

Kyverna Therapeutics (KYTX) Options

Kyverna Therapeutics (NASDAQ:KYTX) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL